The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 970-981

  Rodríguez, Julio Cesar García ^a   Teste, Iliana Sosa ^a  

^a National Center for Laboratory Animal Breeding (CENPALAB)   (Cuba)

Author keywords

Erythropoietin; Nasal delivery; Neuroprotection; Stroke

Indexed keywords

ASIALOERYTHROPOIETIN; CARBAMYLATED ERYTHROPOIETIN; ERYTHROPOIETIN; NEUROERYTHROPOIETIN; RECOMBINANT ERYTHROPOIETIN; SIALIC ACID; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; ERYTHROPOIESIS; HUMAN; LONG TERM CARE; NERVOUS TISSUE; NEUROPROTECTION; NON INVASIVE PROCEDURE; NONHUMAN; REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, INTRANASAL; ANIMALS; ASIALOGLYCOPROTEINS; BLOOD-BRAIN BARRIER; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; RECEPTORS, ERYTHROPOIETIN; STROKE;

ANIMALIA;

EID: 77649279828     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.103     Document Type: Review

References (102)

1. Bacigaluppi, M. and Hermann, D.M. (2008) New targets of neuroprotection in ischemic stroke. TheScientificWorldJOURNAL 8, 698-712.
2. Fagan, S.C., Hess, D.C., Hohnadel, E.J., Pollock, D.M., and Ergul, A. (2004) Targets for vascular protection after acute ischemic stroke. Stroke 35(9), 2220-2225.
3. O'Collins, V.E., Macleod, M.R., Donnan, G.A., Horky, L.L., van der Worp, B.H., and Howells, D.W. (2006) 1,026 experimental treatments in acute stroke. Ann. Neurol. 59(3), 467-477.
4. Grotta, J. (2002) Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 33(1), 306-307.
5. Castillo, J., varez-Sabin, J., Davalos, A., et al. (2003) [Consensus review. Pharmacological neuroprotection in cerebral ischemia: is it still a therapeutic option?]. Neurologia 18(7), 368-384.
6. Fisher, J.W. (2003) Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. 228(1), 1-14.
7. Wang, Y., Zhang, Z., Rhodes, K., Renzi, M., Zhang, R.L., and Kapke, A. (2007) Postischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br. J. Pharmacol. 151, 1377-1384.
8. Wiessner, C., Allegrini, P.R., Ekatodramis, D., Jewell, U.R., Stallmach, T., and Gassmann, M. (2001) Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin. J. Cereb. Blood Flow Metab. 21(7), 857-864.
9. Kalialis, L.V. and Olsen, N.V. (2003) Erythropoietin--a new therapy in cerebral ischemia? Ugeskr. Laeger 165, 2477.
10. Wang, X., Zhu, C., Wang, X., et al. (2004) The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J. Neurochem. 91(4), 900-910.
11. Kirkeby, A., Torup, L., Bochsen, L., et al. (2008) High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO). Thromb. Haemost. 99(4), 720-728.
12. Lapchak, P.A. (2008) Carbamylated erythropoietin to treat neuronal injury: new development strategies. Expert Opin. Investig. Drugs 17(8), 1175-1186. 13. Leist, M., Ghezzi, P., Grasso, G., et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681), 239-242.
13. Sosa, I., García Rodríguez, J.C., Santana, J., et al. (2006) Intranasal administration of recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in Mongolian gerbils. Pharmacology Online 1, 100-112.
14. Sosa, T.I., Mengana, T.Y., García, S.J.D., et al. (2008) Recombinant human erythropoietin as a neuroprotective therapy in brain ischemia. Biotecnol. Aplicada 25, 223-229.
15. Genc, S., Koroglu, T.F., and Genc, K. (2004) Erythropoietin and the nervous system. Brain Res. 1000, 19-31.
16. Sosa, T.I. and García Salman, J.D. (2007) Neuroprotección en la isquemia cerebral. Experiencias con la eritropoyetina humana recombinante. Rev. Ecuat. Neurol. 16(2).
17. Castillo, J. (2002) Luces y Sombras de la neuroprotección en la isquemia cerebral. Universidad de Santiago de Compostela, Santiago de Compostela, España. pp. 95-121.
18. Fisher, M., Rogalewski, A., and Ringelstein, B.E. (2006) Toward a multimodal neuroprotective treatment of stroke. Stroke 37, 1129.
19. Ovbiagele, B., Kidwell, C.S., Starkman, S., and Saver, J.L. (2003) Neuroprotective agents for the treatment of acute ischemic stroke. Curr. Neurol. Neurosci. Rep. 3, 9-20.
20. Digicaylioglu, M. and Lipton, S.A. (2001) Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 412(6847), 641-647.
21. Jelkmann, W. and Wagner, K. (2004) Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann. Hematol. 83(11), 673-686.
22. Wenger, R.H. and Gassmann, M. (1997) Oxygen(es) and the hypoxia-inducible factor-1. Biol. Chem. 378, 609-616.
23. Gassmann, M., Heinicke, K., Soliz, J., and Ogunshola, O. (2003) Non-erythroid functions of erythropoietin. In Hypoxia: Through the Lifecycle. Roach, R.C., Ed. Kluwer Academic/Plenum Publishers, New York. pp. 1-8.
24. Ovbiagele, B., Kidwell, C.S., Starkman, S., and Saver, J.L. (2003) Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke. Curr. Treat. Options Neurol. 5(5), 367-375.
25. Eid, T., Brines, M.L., Cerami, A., et al. (2004) Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. J. Neuropathol. Exp. Neurol. 63(1), 73-83.
26. Marti, H.H. (2004) Erythropoietin and the hypoxic brain. J. Exp. Biol. 207(Pt 18), 3233-3242.
27. Lipšic, E., Schoemaker, R.G., van der Meer, P., Voors, A.A., van Veldhuisen, D., and van Gilst, W.H. (2006) Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. 48(11), 2161-2167.
28. Marti, H.H., Bernaudin, M., Petit, E., and Bauer, C. (2000) Neuroprotection and angiogenesis: dual role of erythropoietin in brain ischemia. News Physiol. Sci. 15(5), 225-229.
29. Belayev, L., Khoutorova, L., Zhao, W., et al. (2005) Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke 36(5), 1071-1076.
30. Catania, M.A., Marciano, M.C., Parisi, A., et al. (2002) Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. Eur. J. Pharmacol. 437(3), 147-150.
31. Siren, A.L., Fratelli, M., Brines, M., et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U. S. A. 98(7), 4044-4049.
32. Chattopadhyay, A., Choudhury, T.D., Bandyopadhyay, D., and Datta, A.G. (2000) Protective effect of erythropoietin on the oxidative damage of erythrocyte membrane by hydroxyl radical. Biochem. Pharmacol. 59, 419-425.
33. Calapai, G., Marciano, M.C., Corica, F., et al. (2000) Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur. J. Pharmacol. 401(3), 349-356.
34. Olsen, N.V. (2003) Central nervous system frontiers for the use of erythropoietin. Clin. Infect. Dis. 37(Suppl 4), 323.
35. Dirnagl, U., Simon, R.P., and Hallenbeck, J.M. (2003) Ischemic tolerance and endogenous neuroprotection. Trends Neurosci. 26(5), 248-254.
36. Kirino, T. (2002) Ischemic tolerance. J. Cereb. Blood Flow Metab. 22, 1283-1296.
37. Chong, Z.Z., Kang, J., and Maiese, K. (2002) Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 106, 2973-2979.
38. Cerami, A., Brines, M., Ghezzi, P., Cerami, C., and Itri, L.M. (2002) Neuroprotective properties of eripthopoietin alfa. Nephrol. Dial. Transplant. 17(Suppl 1), 8.
39. Juul, S. (2002) Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr. Suppl. 91(438), 36-42.
40. Agnello, D., Bigini, P., Villa, P., et al. (2002) Erythropoietin exerts anti-inflammatory effect on the CNS in the model of experimental autoimmune encephalomyelitis. Brain Res. 952, 128-134.
41. Renzi, M.J., Farrell, F.X., Bittner, A., et al. (2002) Erythropoietin induces changes in gene expression in PC-12 cells. Brain. Res. Mol. Brain Res. 104(1), 86-95.
42. Cerami, A., Brines, M.L., Ghezzi, P., and Cerami, C.J. (2001) Effects of epoetin alfa on the central nervous system. Semin. Oncol. 28(2 Suppl 8), 66-70.
43. Juul, S.E., Yachnis, A.T., Rojiani, A.M., and Christensen, R.D. (1999) Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr. Dev. Pathol. 2(2), 148-158.
44. Cardona-Gómez, G.P., Arango-Dávila, C., Gallego-Gómez, J.C., Pimienta, H., and García-Segura, L.M. (2004) Estrogen inhibits glycogen synthase kinase-3b and modulates the interaction of the microtubule-associated protein Tau with glutamate receptor subunits in post-ischemic hippocampus: implications for hormonal neuroprotective mechanisms. Mol. Brain Res. 25, 178-187.
45. Frey, H.W., Liu, J., Chen, X., et al. (1997) Delivery of 125 I-NGF to the brain via the olfactory route. Drug Deliv. 4, 87-92.
46. Nagai, A., Nakagawa, E., and Choi, H.B. (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J. Neuropathol. Exp. Neurol. 60, 386-392.
47. Ruscher, K., Freyer, D., Karsch, M., et al. (2002) Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J. Neurosci. 22(23), 10291-10301.
48. Ehrenreich, H., Hasselblatt, M., Dembowski, C., et al. (2002) Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8(8), 495-505.
49. Siren, A.L., Knerlich, F., and Poser, W. (2001) Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 101, 271-276.
50. Eid, T. and Brines, M. (2002) Recombinant human erythropoietin for neuroprotection: what is the evidence? Clin. Breast Cancer 3(Suppl 3), S109-115.
51. Lundbeck, H. (2009) Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke. Report No. NCT00756249. ClinicalTrials.gov
52. Alafaci, C., Salpietro, F., Grasso, G., et al. (2000) Effect of recombinant human erythropoietin on cerebral ischemia following experimental subarachnoid hemorrhage. Eur. J. Pharmacol. 406(2), 219-225.
53. Sinn, D., Chu, K., and Lee, S. (2005) Erythropoietin has neuroprotective effects with functional recovery in experimental intracerebral hemorrhage. 57th Annual Meeting of the American Academy of Neurology. http://www.abstracts2view. com/aan
54. Lu, D., Mahmood, A., and Qu, C. (2005) Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J. Neurotrauma 22, 1011-1017.
55. Yatsiv, I., Grigoriadis, N., and Simeonidou, C. (2005) Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J. 19(12), 1701-1703.
56. Celik, M., Gokmen, N., and Erbayraktar, S. (2002) Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc. Natl. Acad. Sci. U. S. A. 99, 2258-2263.
57. Gorio, A., Madaschi, L., Di, S.B., et al. (2005) Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc. Natl. Acad. Sci. U. S. A. 102(45), 16379-16384.
58. Sattler, M.B., Merkler, D., Maier, K., et al. (2004) Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis. Cell Death Differ. 11(Suppl 2), S181-192.
59. Diem, R., Sattler, M.B., Merkler, D., et al. (2005) Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain 128(Pt 2), 375-385.
60. Bianchi, R., Buyukakilli, B., Brines, M., et al. (2004) Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl. Acad. Sci. U. S. A. 101(3), 823-828.
61. Becerra, S.P. and Amaral, J. (2002) Erythropoietin-an endogenous retinal survival factor. N. Engl. J. Med. 347, 1968-1970.
62. Ehrenreich, H., Degner, D., Meller, J., et al. (2004) Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol. Psychiatry 9(1), 42-54.
63. Sola, A., Rogido, M., Lee, B.H., Genetta, T., and Wen, T.C. (2005) Erythropoietin after focal cerebral ischemia activates the Janus kinase-signal transducer and activator of transcription signaling pathway and improves brain injury in postnatal day 7 rats. Pediatr. Res. 57(4), 481-487.
64. Kumral, A., Baskin, H., Gokmen, N., et al. (2004) Selective inhibition of nitric oxide in hypoxic-ischemic brain model in newborn rats: is it an explanation for the protective role of erythropoietin? Biol. Neonate 85(1), 51-54.
65. Chang, Y., Mu, D., and Wendland, M. (2005) Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr. Res. 58, 106-111.
66. Shingo, T., Sorokan, S.T., Shimazaki, T., and Weiss, S. (2001) Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J. Neurosci. 21(24), 9733-9743.
67. Marti, H.H., Wenger, R.H., Rivas, L.A., et al. (1996) Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 8(4), 666-676.
68. Juul, S.E., Anderson, D., and Li, Y. (1998) Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr. Res. 43, 40-49.
69. Brines, M., Grasso, G., Fiordaliso, F., et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 101(41), 14907-14912.
70. Murphy, J. and Young, I. (2006) IL-3, IL-5, and GM-CSF signaling: crystal structure of the human beta-common receptor. Vitam. Horm. 74, 1-30.
71. Erbayraktar, S., Grasso, G., Sfacteria, A., et al. (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc. Natl. Acad. Sci. U. S. A. 100(11), 6741-6746.
72. Zhang, J., Li, Y., and Cui, Y. (2005) Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res. 1034, 34-39.
73. Brines, M. and Cerami, A. (2005) Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6(6), 484-494.
74. Villa, P., van Beek, J., Larsen, A.K., et al. (2006) Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J. Cereb. Blood Flow Metab. 27(3), 552-563.
75. Mahmood, A., Lu, D., and Qu, C. (2007) Treatment of traumatic brain injury in rats with erythropoietin and carbamylated erythropoietin. J. Neurosurg. 107(392), 397.
76. King, V.R., Averill, S.A., and Hewazy, D. (2007) Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat. Eur. J. Neurosci. 26, 90-100.
77. Sosa, I. and Garcia Salman, J.D. (2007) Isquemia cerebral y neuroprotección. www.monografias.com\isquemiacerebral\shtml.htm.
78. Savino, C., Pedotti, R., Baggi, F., et al. (2005) Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J. Neuroimmunol. 172(1-2), 27-37.
79. Siren, A.L., Fasshauer, T., Bartels, C., and Ehrenreich, H. (2009) Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system. Neurotherapeutics 6(1), 108-127.
80. Illum, L. (2004) Is nose-to-brain transport of drugs in man a reality? J. Pharm. Pharmacol. 56(1), 3-17.
81. Banks, A.W. (2004) Are the extracellular pathways a conduit for the delivery of therapeutics to the brain? Curr. Pharm. Des. 10, 1365-1370.
82. Ross, T.M., Martinez, P.M., Renner, J.C., Thorne, R.G., Hanson, L.R., and Frey, W.H. (2004) Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. Neuroimmunology 151, 66-77.
83. Liu, X.F., Fawcett, J.R., Thorne, R.G., DeFor, T.A., and Frey, W.H. (2001) Intranasal administration of insulin-like growth factor-I bypasses the blood-brain barrier and protects against focal cerebral ischemic damage. J. Neurol. Sci. 187(1-2), 91-97.
84. Sosa, T.I. (2007) Estudio del efecto neuroprotector de la eritropoyetina humana recombinante con bajo contenido de ácido sialico aplicada por vía intranasal en biomodelos experimentales de isquemia cerebral [Tesis en opción al grado de Dr. en Ciencias Veterinarias]. UNAH.
85. Sosa, I., Cruz, J., Santana, J., et al. (2007) Paso de la molécula de eritropoyetina humana recombinante con bajo contenido de ácido siálico al Sistema nervioso central por la vía intranasal en los modelos del meriones unguiculatus y el primate no humano Macaca fascicularis. Rev. Salud. Anim. 29(2), 1-6.
86. Illum, L. (2002) Nasal drug delivery: new developments and strategies. Drug Discov. Today 7(23), 1184-1189.
87. Pardridge, W.M. (2007) Blood-brain barrier delivery. Drug Discov. Today 12(1-2), 54-61.
88. Chi, O.Z., Hunter, C., Liu, X., and Weiss, H.R. (2008) Effects of erythropoietin on blood-brain barrier disruption in focal cerebral ischemia. Pharmacology 82(1), 38-42.
89. Pathan, S.A., Iqbal, Z., Zaidi, S.M., et al. (2009) CNS drug delivery systems: novel approaches. Recent Pat. Drug Deliv. Formul. 3(1), 71-89.
90. Hanson, L.R. and Frey, W.H. (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. (9 Suppl 3), S5.
91. Fletcher, L., Kohli, S., Sprague, SM., et al. (2009) Intranasal delivery of erythropoietin plus insulin-like growth factor-I for acute neuroprotection in stroke. Laboratory investigation. J. Neurosurg. 111(1), 164-170
92. Thorne, R.G., Pronk, G.J., Padmanabhan, V., and Frey, W.H. (2004) Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 127(2), 481-496.
93. Fiordaliso, F., Chimenti, S., Staszewsky, L., et al. (2005) A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 102(6), 2046-2051.
94. Weber, A., Maier, R.F., Hoffmann, U., et al. (2002) Erythropoietin improves synaptic transmission during and following ischemia in rat hippocampal slice cultures. Brain Res. 958(2), 305-311.
95. Hilger, P.A. (1989) Applied anatomy and physiology of the nose. In Boies Fundamentals of Otolaryngology. 6th ed. Adams, G.L., Boies, L.R., and Hilger, P.A., Ed. W.B. Saunders, Philadelphia.
96. Illum, L. (2003) Nasal drug delivery--possibilities, problems and solutions. J. Control Release 87(1-3), 187-198.
97. Yu, Y.-P., Xu, Q.-Q., Zhang, Q., Zhang, W.-P., Zhang, L.-H., and Wei, E.-Q. (2005) Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci. Lett. 387, 5-10.
98. Nuñez, Y., Bueno, P.V., Carrillo, D.C., et al. (2009) Neuroprotective effect of a nasal formulation of erythropoietin with low sialic acid content. Rev. Cubana Farm. 43(1), 1-13.
99. Muñoz Cernuda, A., León Rodríguez, R., García Rodríguez, J.C., et al., Inventors (2005) Formulaciones nasales de EPOhr con bajo contenido de ácido siálico para el tratamiento de enfermedades del sistema nervioso central. Cuba Patent 20050138.
100. Sosa, I., Mengana, T.Y., Portillo, A., et al. (2007) Ensayo de seguridad de la aplicación nasal de la molécula de rHu-EPO con bajo contenido de ácido siálico en el modelo de ratón B6D2F1. CD VI Congreso Internacional de Ciencias Veterinarias ISBN: 978-959-282-047-3 Animales de laboratorio: 164-171.
101. Maggio, E.T. (2005) Recent Developments in Intranasal Drug Delivery Technology are Creating New Vistas for Peptide and Protein Therapeutics. Drug Delivery (Technology Overviews).
102. Subiros Martínez, N., García Rodríguez, J.C., González Navarro, B., Sosa, I., and García Salman, J.D. (2005) Evaluación histológica del efecto de la eritropoyetina vía intranasal, sobre la muerte neuronal retardada en gerbos sometidos a isquemia cerebral transitoria. Estudio preliminar. 7° Congreso Virtual Hispanoamericano de Anatomía Patológica. Available from: http://www.conganat.org/7congreso/445.pdf